This P50 application is for the renewal of the Mayo SPORE In Brain Cancer for years 6-10. The SPORE will support a multidisciplinary team of basic and applied science investigators to perform translational research directed at significantly reducing morbidity and mortality from malignant gliomas. Brian Patrick O'Neill, M.D. will serve as Overall Principal Investigator and Director of the Administrative Core. Robert B. Jenkins, M.D., Ph.D. will serve as Overall Co-Principal Investigator and Administrative Core Co-Director. The translational research objectives of the SPORE will be directed by 14 investigators from 8 departments at Mayo Clinic in Rochester, all with a demonstrable history of collaborative and translational research. The SPORE comprises 4 Mayo investigator- initiated research projects and 4 scientific core resources consolidated by the Administrative Core. The SPORE also includes career development and developmental research programs. SPORE Research Projects 1. Influence of DNA repair on PARP inhibitor efficacy In GBM (Co-Leaders: J.N. Sarkaria, M.D., and N. Laack, M.D.) 2. Optimizing Measles Virotherapy In the Treatment of Gliomas (Co-Leaders: E. Galanis, M.D., D.Sc. and I.F. Parney, M.D., Ph.D.) 3. The Role of MMSET in DNA damage response and chemoradioresistance of glioblastoma (Co-Leaders: Z. Lou, Ph.D. and J. C. Buckner, M.D.) 4. Clinical Relevance of Chromosome 5p/9p/20q/8q Germline Alterations In Glioma (Co-Leaders: R. B. Jenkins, M.D., Ph.D and P. Yang, M.D., Ph.D. SPORE Scientific Cores A. Administrative Core (Director: B. P. O'Neill, M.D.;Co-Director: R.B. Jenkins, M.D., Ph.D.) B. Biostatistics Core (Director: K.V. Ballman, Ph.D.;Co-Director: W. Wu, Ph.D.) C. Pathology and Tissue Procurement Core (Director: C. Giannini, M.D., Ph.D.;Co-Director: F. Rodriguez, M.D.) D. Animal Core (Director: J.N. Sarkaria, M.D.;Co-Director: I.F. Parney, M.D., Ph.D.) E. Clinical Research Core (Director: J.C. Buckner, M.D.;Co-Director: D. H. Lachance, M.D.) Developmental Research Portfolio

Public Health Relevance

Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility, and adaptive skills. In addition to significant reduction in life expectancy each new malignant gliomas case impacts the nation's public health since its morbidity represents on average twenty years of lost productivity. Whether the payer is public or private, diagnosis and treatment, including supportive care in the terminal stages of disease, extracts enormous health care expenditures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-09
Application #
8729251
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Arnold, Julia T
Project Start
2004-09-20
Project End
2016-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$2,032,907
Indirect Cost
$737,876
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13

Showing the most recent 10 out of 254 publications